# weight loss  

- This trial marks the fourth Phase I peptide study for Ascletis this year.

GUANGZHOU, China

Obese adults without diabetes who received GLP-1 receptor agonists had a 41% lower risk of developing obesity-associated cancers than those who received only dietary and exercise c......

-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model.

- 

Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were delivered by Timothy Garvey, MD, an internationally renowned expert in obesity and metabolic medicine and a scientific advisor to Caliway, garnering significant interest from global experts and multinational pharmaceutical companies.

NEW ORLEANS

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound.

SHANGHAI

When K-pop idols' flawless physiques become the dominant beauty standard, the impact extends well beyond adult consumers — it reaches students who are still minors. South Korea's l......